SOD1 and amyotrophic lateral sclerosis: However, in ALS patients with (likely) pathogenic SOD1 variants, intrathecal application of the antisense oligonucleotide (ASO) tofersen, which reduces the synthesis of SOD1 protein by RNase H-dependent degradation of SOD1 messenger RNA, has recently shown very promising results.18